Search

Your search keyword '"Seras-Franzoso J"' showing total 5 results
Start Over Author "Seras-Franzoso J" Topic recombinant proteins
5 results on '"Seras-Franzoso J"'

1. Nanostructured recombinant cytokines: A highly stable alternative to short-lived prophylactics.

Author

Torrealba D, Parra D, Seras-Franzoso J, Vallejos-Vidal E, Yero D, Gibert I, Villaverde A, Garcia-Fruitós E, and Roher N

Subjects
Animals, Chemokine CCL4 chemistry, Cytokines administration & dosage, Cytokines chemistry, Drug Stability, Hydrogen-Ion Concentration, Kinetics, Nanostructures chemistry, Pseudomonas Infections immunology, Pseudomonas Infections pathology, Recombinant Proteins chemistry, Recombinant Proteins genetics, Treatment Outcome, Tumor Necrosis Factor-alpha genetics, Tumor Necrosis Factor-alpha immunology, Zebrafish, Chemokine CCL4 administration & dosage, Nanostructures administration & dosage, Protein Engineering methods, Pseudomonas Infections prevention & control, Recombinant Proteins adverse effects, Tumor Necrosis Factor-alpha administration & dosage
Abstract

Cytokines have been widely used as adjuvants and therapeutic agents in treatments of human diseases. Despite their recognized potential as drugs, the medical use of cytokines has considerable drawbacks, mainly related to their low stability and short half-life. Such intrinsic limitations imply the administration of high doses, often prompting toxicity, undesirable side effects and greater production costs. Here, we describe a new category of mechanically stable nanostructured cytokines (TNFα and CCL4/MIP-1β) that resist harsh physicochemical conditions in vitro (pH and temperature), while maintaining functionality. These bio-functional materials are produced in recombinant cell factories through cost-effective and fully scalable processes. Notably, we demonstrate their prophylactic potential in vivo showing they protect zebrafish from a lethal infection by Pseudomonas aeruginosa., (Copyright © 2016 Elsevier Ltd. All rights reserved.)

Published
2016
Full Text
View/download PDF

2. Functional protein aggregates: just the tip of the iceberg.

Author

Villaverde A, Corchero JL, Seras-Franzoso J, and Garcia-Fruitós E

Subjects
Animals, Escherichia coli genetics, Gene Expression, Humans, Inclusion Bodies genetics, Inclusion Bodies ultrastructure, Recombinant Proteins chemistry, Recombinant Proteins genetics, Recombinant Proteins isolation & purification, Recombination, Genetic, Solubility, Up-Regulation, Escherichia coli metabolism, Inclusion Bodies metabolism, Protein Aggregates, Recombinant Proteins metabolism
Abstract

An increasing number of both prokaryotic and eukaryotic cell types are being adapted as platforms for recombinant protein production. The overproduction of proteins in such expression systems leads to the formation of insoluble protein-based aggregates. Although these protein clusters have been poorly studied in most of the eukaryotic systems, aggregates formed in E. coli, named inclusion bodies (IBs), have been deeply characterized in the last decades. Contrary to the general belief, an important fraction of the protein embedded in IB is functional, showing promise in biocatalysis, regenerative medicine and cell therapy. Thus, the exploration of all these functional protein clusters would largely expand their potential in both pharma and biotech industry.

Published
2015
Full Text
View/download PDF

3. Functional inclusion bodies produced in bacteria as naturally occurring nanopills for advanced cell therapies.

Author

Vázquez E, Corchero JL, Burgueño JF, Seras-Franzoso J, Kosoy A, Bosser R, Mendoza R, Martínez-Láinez JM, Rinas U, Fernández E, Ruiz-Avila L, García-Fruitós E, and Villaverde A

Subjects
Animals, Catalase administration & dosage, Catalase therapeutic use, Cell Line, Cell Membrane Permeability, Green Fluorescent Proteins administration & dosage, HSP70 Heat-Shock Proteins administration & dosage, HSP70 Heat-Shock Proteins therapeutic use, HeLa Cells, Humans, Leukemia Inhibitory Factor administration & dosage, Leukemia Inhibitory Factor therapeutic use, Mice, Recombinant Proteins therapeutic use, Tetrahydrofolate Dehydrogenase administration & dosage, Tetrahydrofolate Dehydrogenase therapeutic use, Delayed-Action Preparations metabolism, Escherichia coli metabolism, Inclusion Bodies metabolism, Recombinant Proteins administration & dosage
Abstract

Inclusion bodies (50-500 nm in diameter) produced in recombinant bacteria can be engineered to contain functional proteins with therapeutic potential. Upon exposure, these protein particles are efficiently internalized by mammalian cells and promote recovery from diverse stresses. Being fully biocompatible, inclusion bodies are a novel platform, as tailored nanopills, for sustained drug release in advanced cell therapies., (Copyright © 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.)

Published
2012
Full Text
View/download PDF

4. Extracellular vesicles from recombinant cell factories improve the activity and efficacy of enzymes defective in lysosomal storage disorders

Author

Rosa Mendoza, Zamira V. Díaz-Riascos, Sandra Mancilla, Lorenzo Albertazzi, Natalia García-Aranda, Ana Boullosa, Antonio Villaverde, Monica Mandaña, Patricia González, Ibane Abasolo, Anna Rosell, Guillem Pintos-Morell, José Luis Corchero, Josefina Casas, Simó Schwartz, Alba Grayston, Joaquin Seras-Franzoso, Roger Riera, Elena García-Fruitós, Marc Moltó-Abad, Institut Català de la Salut, [Seras-Franzoso J, González P, Schwartz S Jr] Drug Delivery & Targeting, CIBBIM-Nanomedicine, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Barcelona, Spain. [Díaz-Riascos ZV, García-Aranda N, Mandaña M, Boullosa A, Mancilla S, Abasolo I] Drug Delivery & Targeting, CIBBIM-Nanomedicine, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Barcelona, Spain. Functional Validation & Preclinical Research (FVPR), CIBBIM-Nanomedicine, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Corchero JL] Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Barcelona, Spain. Institut de Biotecnologia i de Biomedicina (IBB) and Department of Genetics and Microbiology, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Grayston A, Rosell A] Neurovascular Research Laboratory, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Moltó-Abad M, Pintos-Morell G] Drug Delivery & Targeting, CIBBIM-Nanomedicine, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Division of Rare Diseases, Reference Center for Hereditary Metabolic Disorders (CSUR, XUEC, MetabERN, and CIBER-ER). Vall d’Hebron Hospital Universitari, Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus

Subjects
Male, 0301 basic medicine, Hydrolases, Cell, Sanfilippo syndrome, Otros calificadores::Otros calificadores::Otros calificadores::/enzimología [Otros calificadores], law.invention, Mice, chemistry.chemical_compound, 0302 clinical medicine, law, Cells::Cellular Structures::Extracellular Space::Extracellular Vesicles [ANATOMY], Cloning, Molecular, Research Articles, Mice, Knockout, chemistry.chemical_classification, Trihexosylceramides, Brain, Enzyme replacement therapy, Recombinant Proteins, Cell biology, N-sulfoglucosamine sulfohydrolase, medicine.anatomical_structure, Metabolisme - Trastorns, 030220 oncology & carcinogenesis, Recombinant DNA, Pharmaceutical Vehicles, Research Article, Histology, Globotriaosylceramide, CHO Cells, Nutritional and Metabolic Diseases::Metabolic Diseases::Metabolism, Inborn Errors::Lysosomal Storage Diseases [DISEASES], Lysosomal storage disorders, Enzims extracel·lulars - Ús terapèutic, lysosomal storage disorders, Extracellular Vesicles, 03 medical and health sciences, Cricetulus, In vivo, medicine, Animals, Humans, Alpha-galactosidase A, enfermedades nutricionales y metabólicas::enfermedades metabólicas::alteraciones congénitas del metabolismo::enfermedades por almacenamiento lisosómico [ENFERMEDADES], Fabry disease, QH573-671, alpha‐galactosidase A, células::estructuras celulares::espacio extracelular::vesículas extracelulares [ANATOMÍA], N‐sulfoglucosamine sulfohydrolase, Cell Biology, medicine.disease, Lysosomal Storage Diseases, Mice, Inbred C57BL, HEK293 Cells, 030104 developmental biology, Enzyme, chemistry, alpha-Galactosidase, Drug delivery, Lysosomes, Cytology, Other subheadings::Other subheadings::Other subheadings::/enzymology [Other subheadings]
Abstract

In the present study the use of extracellular vesicles (EVs) as vehicles for therapeutic enzymes in lysosomal storage disorders was explored. EVs were isolated from mammalian cells overexpressing alpha‐galactosidase A (GLA) or N‐sulfoglucosamine sulfohydrolase (SGSH) enzymes, defective in Fabry and Sanfilippo A diseases, respectively. Direct purification of EVs from cell supernatants was found to be a simple and efficient method to obtain highly active GLA and SGSH proteins, even after EV lyophilization. Likewise, EVs carrying GLA (EV‐GLA) were rapidly uptaken and reached the lysosomes in cellular models of Fabry disease, restoring lysosomal functionality much more efficiently than the recombinant enzyme in clinical use. In vivo, EVs were well tolerated and distributed among all main organs, including the brain. DiR‐labelled EVs were localized in brain parenchyma 1 h after intra‐arterial (internal carotid artery) or intravenous (tail vein) administrations. Moreover, a single intravenous administration of EV‐GLA was able to reduce globotriaosylceramide (Gb3) substrate levels in clinically relevant tissues, such kidneys and brain. Overall, our results demonstrate that EVs from cells overexpressing lysosomal enzymes act as natural protein delivery systems, improving the activity and the efficacy of the recombinant proteins and facilitating their access to organs neglected by conventional enzyme replacement therapies., This study has been supported by ISCIII (PI18_00871 co‐founded by Fondo Europeo de Desarrollo Regional (FEDER)), and CIBER‐BBN (EXPLORE) granted to IA. Different CIBER‐BBN units of ICTS ‘NANBIOSIS’ have participated in this work (https://www.nanbiosis.es/platform-units/), more specifically the U1/Protein Production Platform for protein purification, Unit 6 for NTA analysis and TFF purification and U20/FVPR for in vivo assays.

Published
2021

5. Targeting antitumoral proteins to breast cancer by local administration of functional inclusion bodies

Author

Pesarrodona, M., Pesarrodona, Mireia, Jauset, Toni, Díaz-Riascos, Zamira V., Sánchez-Chardi, Alejandro, Beaulieu, Marie Eve, Seras-Franzoso, Joaquin, Sánchez-García, Laura, Baltà-Foix, Ricardo, Mancilla, Sandra, Fernández, Yolanda, Rinas, Ursula, Schwartz, Simó, Soucek, Laura, Villaverde, Antonio, Abasolo, Ibane, Vázquez, Esther, [Pesarrodona M] Institut de Biotecnologia i de Biomedicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. CIBER de Bioingeniería Biomateriales y Nanomedicina (CIBER-BBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain. [Jauset T, Beaulieu ME] Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. Peptomyc S.L. Edifici Cellex, Barcelona, Spain. [Díaz-Riascos ZV, Mancilla S, Fernández Y, Abasolo I] CIBER de Bioingeniería Biomateriales y Nanomedicina (CIBER-BBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain. CIBBIM-Nanomedicina Àrea de Validació Funcional i Estudis Preclínics, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Barcelona Spain. CIBBIM-Nanomedicina Direccionament i Alliberament Farmacològic, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain. [Sánchez-Chardi A] Departament de Biologia Evolutiva Ecologia i Ciències Ambientals, Facultat de Biologia, Universitat de Barcelona, Barcelona Spain. [Seras-Franzoso J, Baltà-Foix R] CIBBIM-Nanomedicina Direccionament i Alliberament Farmacològic, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Barcelona, Spain. [Schwartz Jr S] CIBER de Bioingeniería Biomateriales y Nanomedicina (CIBER-BBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain. CIBBIM-Nanomedicina Direccionament i Alliberament Farmacològic, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Barcelona, Spain. [Soucek L] Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. Peptomyc S.L. Edifici Cellex, Barcelona, Spain. Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain. Department of Biochemistry and Molecular Biology, Universitat Autònoma de Barcelona, Bellaterra, Spain, Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, and HZI,Helmholtz-Zentrum für Infektionsforschung GmbH, Inhoffenstr. 7,38124 Braunschweig, Germany.

Subjects
Cancer therapy, General Chemical Engineering, Neoplasms::Neoplasms by Site::Breast Neoplasms [DISEASES], neoplasias::neoplasias por localización::neoplasias de la mama [ENFERMEDADES], General Physics and Astronomy, Medicine (miscellaneous), Diseases, inclusion bodies, Biofabrication, 02 engineering and technology, 01 natural sciences, Inclusion bodies, law.invention, Medicaments antineoplàstics, Mama - Càncer, law, General Materials Science, lcsh:Science, Controlled drug delivery, Recombinant proteins, Functional amyloids, Targeted drug delivery, Full Paper, biology, Chemistry, General Engineering, Full Papers, 021001 nanoscience & nanotechnology, 3. Good health, Human form models, functional amyloids, Recombinant DNA, cancer therapy, Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents [CHEMICALS AND DRUGS], 0210 nano-technology, ddc:624, 010402 general chemistry, Biochemistry, Genetics and Molecular Biology (miscellaneous), Protein drug release, Breast cancer, Proteïnes recombinants, medicine, biofabrication, CD44, Cancer, acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antineoplásicos [COMPUESTOS QUÍMICOS Y DROGAS], células::estructuras celulares::cuerpos de inclusión [ANATOMÍA], Neoplasias::Neoplasias por Localización::Neoplasias de la Mama [ENFERMEDADES], medicine.disease, 0104 chemical sciences, Protein materials, biology.protein, Cancer research, lcsh:Q, Protein drugs, protein drug release, Cells::Cellular Structures::Inclusion Bodies [ANATOMY], ddc:600, Human breast
Abstract

Biofabrication; Cancer therapy; Functional amyloids Biofabricación; Terapia contra el cáncer; Amiloides funcionales Biofabricació; Teràpia contra el càncer; Amiloides funcionals Two structurally and functionally unrelated proteins, namely Omomyc and p31, are engineered as CD44-targeted inclusion bodies produced in recombinant bacteria. In this unusual particulate form, both types of protein materials selectively penetrate and kill CD44+ tumor cells in culture, and upon local administration, promote destruction of tumoral tissue in orthotropic mouse models of human breast cancer. These findings support the concept of bacterial inclusion bodies as versatile protein materials suitable for application in chronic diseases that, like cancer, can benefit from a local slow release of therapeutic proteins. This study has been supported by La Fundacio Marato TV3 and NanoCanTri (CIBER-BBN) to E.V. and I.A., and partially by ISCIII (PI15/00272 and PI1702242 co-founded by Fondo Europeo de Desarrollo Regional (FEDER), to E.V. and S.S., respectively), and Agencia Estatal de Investigacion (AEI) and FEDER (BIO2016-76063-R, AEI/FEDER, UE), AGAUR (2017SGR-229) and CIBER-BBN (VENOM4CANCER) granted to A.V. Protein production and DLS have been partially performed by the ICTS "NANBIOSIS," more specifically by the Protein Production Platform of CIBER-BBN/IBB () and the Biomaterial Processing and Nanostructuring Unit (), respectively. Biodistribution and immunohistochemistry assays were performed at the ICTS "NANBIOSIS," specifically by U20/FVPR (). L.S.-G. was supported by predoctoral fellowship from AGAUR (2018FI_B2_00051). L.S. was supported by the European Research Council (CoG #617473) and the Instituto de Salud Carlos III (FIS #PI16/01224). J.S.-F. was supported by an AECC post-doctoral fellowship. A.V. received an ICREA ACADEMIA award

Catalog

Books, media, physical & digital resources
See catalog results